Preclinical
Phase 2
Nonclinical
Discovery
Phase 1
ERX-315
Metastatic Breast Cancer
Ovarian Cancer
ERX-208
ERX-41
Pancreatic Cancer
ERX-342
Glioblastoma
ER+MT MBC
TX-542
Pipeline
Our innovative molecular platform is the basis for first-in-class targeted therapies treating a broad range of tumors.